HeartBeam Granted Two More U.S. Patents

HeartBeam has received two new patents on its core vector electrocardiography (VECG) from the U.S. Patent and Trademark Office. The company now has 14 issued and allowed U.S. patents and four international patents for the technology.
 
VECG technology collects 3D signals from the heart and converts them into a 12-lead ECG.
 
The first patent covers apparatuses and methods that facilitate the comparison of cardiac signals over time for the automated or assisted detection of heart attacks. For each patient, HeartBeam offers a comparative baseline ECG which helps physicians gain richer insights about cardiac health.
 
The second patent covers methods and apparatuses around the company’s wrist-based ECG system. This is the second patent related to HeartBeam’s watch concept, which combines a continuous ECG monitor with the ability to take a high sensitivity 12-lead ECG in a single device worn on the wrist.
 
“HeartBeam’s core VECG technology is designed to be used with portable, patient-friendly devices such as a credit-card sized system, an extended wear patch, or watch to enable physicians to monitor patients and identify cardiac health trends outside of a medical facility,” said HeartBeam founder and CEO Branislav Vajdic, Ph.D. “These new patents reinforce our strategic vision which is founded on developing and protecting our novel VECG technology and product pipeline as we work to transform how cardiac care is delivered in the future.”
 
HeartBeam also has 20 pending patent applications worldwide. The company expanded its scientific and advisory board last month, as well.